News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,504 Results
Type
Article (14271)
Company Profile (281)
Press Release (253952)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79607)
Career Advice (170)
Deals (13238)
Drug Delivery (35)
Drug Development (50493)
Employer Resources (31)
FDA (5727)
Job Trends (5140)
News (144567)
Policy (10040)
Tag
Academia (915)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21691)
ALS (64)
Alzheimer's disease (848)
Antibody-drug conjugate (ADC) (102)
Approvals (5754)
Artificial intelligence (126)
Autoimmune disease (19)
Automation (5)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (156)
Cancer (1491)
Cardiovascular disease (117)
Career advice (144)
Career pathing (2)
CAR-T (119)
Cell therapy (334)
Cervical cancer (8)
Clinical research (41140)
Collaboration (543)
Compensation (270)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (167)
Cystic fibrosis (76)
Data (1541)
Denatured (11)
Depression (31)
Diabetes (140)
Diagnostics (1301)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29927)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48687)
Executive appointments (468)
FDA (6446)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (501)
Gene editing (98)
Generative AI (10)
Gene therapy (256)
GLP-1 (367)
Government (1081)
Grass and pollen (2)
Guidances (33)
Healthcare (6598)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (116)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (22)
IPO (7276)
IRA (11)
Job creations (865)
Job search strategy (138)
Kidney cancer (7)
Labor market (5)
Layoffs (211)
Leadership (3)
Legal (1389)
Liver cancer (34)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2603)
Medtech (2604)
Mergers & acquisitions (6294)
Metabolic disorders (392)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (69)
Neuropsychiatric disorders (25)
Neuroscience (1261)
NextGen: Class of 2025 (2018)
Non-profit (852)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (45)
Pancreatic cancer (57)
Parkinson's disease (121)
Partnered (8)
Patents (132)
Patient recruitment (79)
Peanut (35)
People (25678)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14526)
Phase II (19139)
Phase III (12097)
Pipeline (831)
Policy (46)
Postmarket research (854)
Preclinical (6147)
Press Release (30)
Prostate cancer (63)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1420)
Recruiting (12)
Regulatory (8659)
Reports (15)
Research institute (939)
Resumes & cover letters (20)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (65)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1977)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (10)
The Weekly (36)
Vaccines (215)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (93)
Last 7 days (446)
Last 30 days (1511)
Last 365 days (19539)
2025 (6470)
2024 (20556)
2023 (22416)
2022 (26829)
2021 (27810)
2020 (23364)
2019 (16240)
2018 (11746)
2017 (13746)
2016 (11852)
2015 (14353)
2014 (10406)
2013 (7506)
2012 (7569)
2011 (7635)
2010 (7439)
Location
Africa (148)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17328)
Australia (2938)
California (3920)
Canada (1154)
China (365)
Colorado (149)
Connecticut (152)
Delaware (105)
Europe (37284)
Florida (469)
Georgia (117)
Idaho (16)
Illinois (235)
India (10)
Indiana (93)
Iowa (2)
Japan (77)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (479)
Massachusetts (3117)
Michigan (70)
Minnesota (146)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (978)
New Mexico (12)
New York (1057)
North Carolina (559)
North Dakota (5)
Northern California (1732)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (748)
Puerto Rico (6)
Rhode Island (19)
South America (208)
South Carolina (4)
Southern California (1513)
Tennessee (25)
Texas (453)
United States (13424)
Utah (55)
Virginia (80)
Washington D.C. (31)
Washington State (353)
Wisconsin (15)
268,504 Results for "rapt therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
RAPT Therapeutics to Participate in Upcoming March 2025 Investor Conferences
March 10, 2025
·
1 min read
Press Releases
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
March 6, 2025
·
8 min read
Press Releases
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
April 15, 2025
·
5 min read
Press Releases
RAPT Therapeutics Announces $150 Million Private Placement
December 23, 2024
·
4 min read
Press Releases
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Business
RAPT Therapeutics Reports First Quarter 2024 Financial Results
RAPT Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
7 min read
Press Releases
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
January 6, 2025
·
4 min read
Press Releases
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
November 13, 2024
·
6 min read
Press Releases
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
December 23, 2024
·
7 min read
Drug Development
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma.
February 20, 2024
·
4 min read
1 of 26,851
Next
